Parkinson's disease dementia

Current Psychiatry Reviews

Volumn 5, Issue 3, 2009, Pages 218-225

  Robottom, Bradley J ^a   Weiner, William J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholinesterase inhibitors; Cognitive dysfunction; Dementia; Dementia with Lewy bodies; Neuropsychiatry; Parkinson's disease

Indexed keywords

AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; QUETIAPINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ANXIETY; BEHAVIOR DISORDER; BRAIN ATROPHY; BRAIN DEPTH STIMULATION; CIGARETTE SMOKING; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; FAMILY HISTORY; HUMAN; LANGUAGE DISABILITY; LEWY BODY; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPIL THREAD; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR;

EID: 70449570531     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340009788971128     Document Type: Review

References (110)

1. Parkinson J. An essay on the shaking palsy. Sherwood, Neely and Jones, London. 1817.
2. Biggins CA, Boyd JL, Harrop FM, et al. A controlled, longitudinal study of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 566-571.
3. Emre M. Dementia in Parkinson's disease: cause and treatment. Curr Opin Neurol 2004; 17: 399-404. (Pubitemid 39071415)
4. Hobson P and Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004; 19: 1943-11049 (Pubitemid 39302836)
5. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002; 51: 722-729. (Pubitemid 34568851)
6. de Lau LM, Schipper CM, Hofman A, et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam study. Arch Neurol 2005; 62: 1265-1269. (Pubitemid 41168354)
7. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844.
8. Aarsland D, Zaccai J, Brayne C. A systemic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20: 1255-1263. (Pubitemid 41645899)
9. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000; 54: 1596-1603. (Pubitemid 30226802)
10. Aarsland D, Anderson K, Larsen JP, et al. Risk of dementia in Parkinson's disease. Neurology 2001; 56: 730-736
11. Marder K, Tang MX, Cote L, et al. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1996; 52: 695-701.
12. Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000; 55: 539-544 (Pubitemid 30647252)
13. Pillon B, Dubois B, Cusimano G, et al. Does cognitive impairment in Parkinson's disease result from nondopaminergic lesions? J Neurol Neurosurg Psychiatry 1989; 52: 201-206
14. Levy G, Tang MX, Cote LJ, et al. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. Mov Disord 2002; 17: 250-257 (Pubitemid 36041293)
15. Ebmeier KP, Calder SA, Crawford JR, et al. Clinical features predicting dementia in idiopathic Parkinson's disease: a follow-up study. Neurology 1990; 40: 1222-1224.
16. Morens DM, Grandinetti A, Reed D, et al. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995; 45: 1041-1051.
17. Marder K, Flood P, Cote L, et al. A pilot study of risk factors for dementia in Parkinson's disease. Mov Disord 1990; 5: 156-161 (Pubitemid 20166192)
18. Marder K, Tang MX, Alfaro B, et al. Risk of Alzheimer's disease in relatives of Parkinson's disease patients with and without dementia. Neurology 1999; 52: 719-724 (Pubitemid 29120173)
19. Rippon GA and Marder KS Dementia in Parkinson's disease. In Anderson KE, Weiner WJ, Lang AE, Ed. Advances in Neurology: Behavioral Neurology of Movement Disorders. Baltimore, Lippincott, Williams, and Wilkins 2005; Vol.96: 95-113.
20. Levin BE, Llabre MM, Weiner WJ Cognitive impairment associated with early Parkinson's disease. Neurology 1989; 39: 557-561 (Pubitemid 19105774)
21. Cooper JA, Sagar HJ, Jordan N, et al. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991; 114: 2095-2122.
22. Pillon B, Dubois B, Agid Y. Testing cognition may contribute to the diagnosis of movement disorders. Neurology 1996; 46: 329-334 (Pubitemid 26081308)
23. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-237
24. Levin BE and Katzen HL. Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease. In Anderson KE, Weiner WJ, Lang AE, Ed. Advances in Neurology: Behavioral Neurology of Movement Disorders. Baltimore, Lippincott, Williams, and Wilkins 2005; Vol.96: 84-94.
25. Canavan AGM. The performance on learning tasks of patients in the early stages of Parkinson's disease. Neuropsychologia 1989; 27: 141-156. (Pubitemid 19084932)
26. Litvan I, Mohr E, Williams J, et al. Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1991; 54: 25-29
27. Paolo AM, Axelrod BM, Troster AI, et al. Utility of a Wisconsin card sorting test short form in persons with Alzheimer's and Parkinson's disease. J Clin Exp Neuropsychol 1996; 18: 892-897
28. Aarsland D, Litvan I, Salmon D, et al. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74: 1215-1220 (Pubitemid 37152244)
29. Noe E, Marder K, Bell KL, et al. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord 2004; 19: 60-67 (Pubitemid 38559622)
30. Huber SJ, Shuttleworth EC, Freidenberg DL. Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases. Arch Neurol 1989; 46: 1287-1291 (Pubitemid 20013359)
31. Pillon B, Deweer B, Agid Y, et al. Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol 1993; 50: 374-379 (Pubitemid 23105460)
32. Girotti F, Soliveri P, Carella F, et al. Dementia and cognitive impairment in Parkinson's disease. J Neurol Neurosrug Psychiatry 1988; 51: 1498-1502. (Pubitemid 19026519)
33. Noe E, Marder K, Bell KL, et al. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord 2003; 19: 60-67
34. Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs. DLB with parkinsonism. Neurology 2002; 59: 1714-1720
35. Stern Y, Richards M, Sano M, et al. Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease. Arch Neurol 1993; 50: 1040-1045 (Pubitemid 23301248)
36. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707 (Pubitemid 47597592)
37. Levin BE. Spatial cognition in Parkinson's disease. Alzheimer's Dis Assoc Disord 1990; 4: 161-170
38. Sharpe MH. Distractibility in early Parkinson's disease. Cortex 1990; 26: 239-246
39. Postle BR., Jonides J, Smith EE. Spatial, but no object, delayed response is impaired in early Parkinson's disease. Neuropsychology 1997; 11: 171-179 (Pubitemid 27211805)
40. Farina E, Gattellaro G, Pomati S. Researching a differential impairment of frontal functions and explicit memory in early Parkinson's disease. Eur J Neurol 2000; 7: 259-267 (Pubitemid 32250658)
41. Dujardin K, Blairy S, Defebvre L, et al. Deficits in decoding emotional facial expressions in Parkinson's disease. Neuropsychologia 2004; 42: 239-250. (Pubitemid 37476404)
42. Boller F, Passafiume D, Keefe NC, et al. Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors. Arch Neurol 1984; 41: 485-490
43. Mosimann UP, Mather G, Wesnes KA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004; 63: 2091-2096 (Pubitemid 39636257)
44. Cahn-Weiner DA, Grace J, Ott BR, et al. Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15: 79-87. (Pubitemid 34625859)
45. Cummings JL, Darkins A, Mendez M, et al. Alzheimer's disease and Parkinson's disease: comparison of speech and language alterations. Neurology 1988; 38: 680-684 (Pubitemid 18118699)
46. Grossman M, Carvell S, Stern MB, et al. Sentence comprehension in Parkinson's disease: the role of attention and memory. Brain Lang 1992; 42: 347-384
47. Lewis FM, Lapointe LL, Murdoch BE, et al. Language impairment in Parkinson's disease. Aphasiology 1998; 12: 193-206.
48. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm 2000; 107: 59-71. (Pubitemid 30077043)
49. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors. Brain 2000; 123: 733-745 (Pubitemid 30162723)
50. Aarsland D, Ballard C, Larsen JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001; 16: 528-536 (Pubitemid 32492388)
51. Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with PD and dementia: frequency, profile, and associated caregiver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42. (Pubitemid 46048261)
52. Wilson RS, Gilley DW, Bennett DA, Beckett LA, Evans DA. Hallucinations, delusions, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2000; 69: 172-177 (Pubitemid 30466020)
53. Starkstein SE, Sabe L, Petracca G, et al. Neuropscyhological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia. J Neurol Neurosurg Psychiatry 1996; 61: 381-387 (Pubitemid 26355780)
54. Mosimann UP, Rowan EN, Partington CE, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry 2006; 14: 153-160 (Pubitemid 43227638)
55. Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938-942. (Pubitemid 30637303)
56. Menza MA, Robertson HD, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34: 465-470 (Pubitemid 23337729)
57. Levy G, Jacobs DM, Tang MX, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord 2002; 17: 1221-1226 (Pubitemid 36050002)
58. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130: 1787-1798. (Pubitemid 47343805)
59. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993; 52: 183-191
60. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211. (Pubitemid 36007810)
61. Galvin JE, Lee VMY, Trojanowski JQ. Synucleinopathies. Clinical and pathological implications. Arch Neurol 2001; 58: 186-190
62. Braak H, Del Tredici K, Bohl J, et al. Pathological changes in the parahippocampal region in select non-Alzheimer dementias. Ann NY Acad Sci 2000; 911: 221-239 (Pubitemid 30462085)
63. Zgaljardic DJ, Foldi NS, Borod JC. Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions. J Neural Transm 2004; 111: 1287-1301
64. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, communitybased study. Ann Neurol 2005; 58: 773-776 (Pubitemid 41552553)
65. Braak H, Rub U, Steur J, Del Tredici K, de Vos RAI. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64: 1404-1410 (Pubitemid 40570509)
66. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's-disease related pathology. Cell Tissue Res 2004; 318: 121-134 (Pubitemid 39362633)
67. Chui HC, Mortimer JA, Slager U, et al. Pathologic correlates of dementia in Parkinson's disease. Arch Neurol 1986; 43: 991-995 (Pubitemid 16023663)
68. Zweig RM, Cardillo JE, Cohen M, et al. The locus ceruleus and dementia in Parkinson's disease. Neurology 1993; 43: 986-991 (Pubitemid 23150574)
69. Bohnen NI, Kaufer DI, Ivanco LS. Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer disease. Arch Neurol 2003; 60: 1745-1748
70. Whitehouse PJ, Hedreen JC, White CL, et al. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983; 13: 243-248
71. Korczyn AD. Dementia in Parkinson's disease. J Neurol 2001; 248(Suppl 3): 1-4.
72. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991; 50: 743-755
73. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259
74. Apaydin H, Ahlskog JE, Parisi JE, et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59: 102-112 (Pubitemid 34052562)
75. Huber SJ, Shuttleworth EC, Christy JA, et al. Magnetic resonance imaging in dementia of Parkinson's disease. J Neurol Neurosurg Psychiatry 1989; 52: 1221-1227 (Pubitemid 20002860)
76. Hanyu H, Asano T, Sakurai H, et al. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am J Neuroradiol 2002; 23: 27-32. (Pubitemid 34098257)
77. Junque C, Ramirez-Ruiz B, Tolosa E, et al. Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. Mov Disord 2005; 20: 540-544 (Pubitemid 40862250)
78. Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996; 46: 678-681 (Pubitemid 26099632)
79. Burton EJ, McKeith IG, Burn DJ, et al. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005; 20: 1571-1576
80. Tachibana H, Kawabata K, Tomino Y, et al. Brain perfusion imaging in Parkinson's disease and Alzheimer's disease demonstrated by three-dimensional surface display with 123I-iodoamphetamine. Dementia 1993; 4: 334-341 (Pubitemid 23355774)
81. Antonini A, De Notaris R, Benti R, et al. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neurol Sci 2001; 22: 45-46 (Pubitemid 33622083)
82. Firbank MJ, Colloby SJ, Burn DJ, et al. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage 2003; 20: 1309-1319. (Pubitemid 37268148)
83. Peppard RF, Martin WR, Carr GD, et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992; 49: 1262-1268
84. Goto I, Taniwaki T, Hosokawa S, et al. Positron emission topographic (PET) studies in dementia. J Neurol Sci 1993; 114: 1-6. (Pubitemid 23025200)
85. Vander Borght T, Minoshima S, Giordani B, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 1997; 38: 797-802.
86. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999; 52: 541-546 (Pubitemid 29075600)
87. Brooks DJ. Technology insight: imaging neurodegeneration in Parkinson's disease. Nat Clin Pract Neurol 2008; 4: 267-277 (Pubitemid 351639547)
88. Kuhl DE, Minoshima S, Fesslar JA, et al. In vivo mapping of cholinergic terminals in early aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996; 40: 399-410.
89. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-1722 (Pubitemid 43754399)
90. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society Task Force. Mov Disord 2007; 22: 2314-2324 (Pubitemid 351155975)
91. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005; 65: 1863-1872 (Pubitemid 43970103)
92. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-819 (Pubitemid 46568532)
93. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show bundant striatal pathology in Lewy body diseases. Ann Neurol 2002; 52: 205-210
94. Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708-712 (Pubitemid 34557010)
95. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-939 (Pubitemid 40909549)
96. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004; 19: 1-8. (Pubitemid 38180686)
97. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Neurology 2006; 66: 996-1002.
98. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518 (Pubitemid 39603164)
99. Giladi N, Shabtai H, Gurevich T, et al. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 2003; 108: 368-373 (Pubitemid 37357643)
100. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 324-325
101. Aarsland D. Galantamine for Parkinson's disease with dementia. Eur Neuropsychopharm 2002; 12(Suppl 3): 378-379
102. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757-763 (Pubitemid 29114294)
103. Ondo WG, Tintner R, Dat Voung K, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20: 958-963 (Pubitemid 41419510)
104. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months duration. Mov Disord 2007; 22: 313-318 (Pubitemid 46569682)
105. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1171-1174
106. Bergman J, Vladimir L. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25: 107-110 (Pubitemid 34411830)
107. Burn D, Emre M, McKeith IG, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2005; 21: 1899-1907.
108. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308-312
109. Defer G, Widner H, Marie R, Remy P, Levivier M, CAPSIT-PD Conference Participants. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999; 14: 572-584. (Pubitemid 30011449)
110. Hughes TA, Ross HF, Mindham RHS, Spokes EGS. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004; 110: 118-123